{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=10", "query": { "intervention": "ipilimumab", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 640, "total_pages": 64, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T18:04:13.880Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04840589", "title": "Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Platinum-Resistant Ovarian Carcinoma", "Refractory Ovarian Carcinoma" ], "interventions": [ { "name": "BET Bromodomain Inhibitor ZEN-3694", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2022-02-02", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-24T18:04:13.880Z", "location_count": 9, "location_summary": "Bethesda, Maryland • New York, New York • The Bronx, New York + 3 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04840589" }, { "nct_id": "NCT01377389", "title": "Ipilimumab + Androgen Depravation Therapy in Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2011-06-17", "completion_date": "2017-04-07", "has_results": true, "last_update_posted_date": "2023-09-29", "last_synced_at": "2026-10-24T18:04:13.880Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01377389" }, { "nct_id": "NCT03520686", "title": "Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "NAI + Pembrolizumab", "type": "DRUG" }, { "name": "NAI + Nivolumab + Ipilimumab", "type": "DRUG" }, { "name": "NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI", "type": "DRUG" }, { "name": "Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI", "type": "DRUG" }, { "name": "Carboplatin + Nab-paclitaxel + Atezolizumab + NAI", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel", "type": "DRUG" }, { "name": "Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin and Nab-paclitaxel plus Atezolizumab", "type": "DRUG" }, { "name": "Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2018-05-18", "completion_date": "2025-10-13", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-24T18:04:13.880Z", "location_count": 31, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03520686" }, { "nct_id": "NCT05262556", "title": "NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastroenteropancreatic Neuroendocrine Tumor", "Gastroenteropancreatic Neuroendocrine Neoplasm", "Neuroendocrine Carcinoma", "Mixed Neuroendocrine-Non Neuroendocrine Neoplasm" ], "interventions": [ { "name": "NP-101 (TQ Formula)", "type": "DRUG" }, { "name": "Nivolumab (3mg/kg)", "type": "DRUG" }, { "name": "Ipilimumab (1mg/kg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amr Mohamed MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 15, "start_date": "2022-12-15", "completion_date": "2025-10-27", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-24T18:04:13.880Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05262556" }, { "nct_id": "NCT07689175", "title": "Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma (HCC)" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab (3 mg/kg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-08-21", "completion_date": "2032-10-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-24T18:04:13.880Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07689175" }, { "nct_id": "NCT05284214", "title": "Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Solid Tumor, Adult" ], "interventions": [ { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Ipilimumab-containing therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Partner Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-01", "completion_date": "2025-09", "has_results": false, "last_update_posted_date": "2023-09-15", "last_synced_at": "2026-10-24T18:04:13.880Z", "location_count": 1, "location_summary": "Lexington, Massachusetts", "locations": [ { "city": "Lexington", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05284214" }, { "nct_id": "NCT02060188", "title": "A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microsatellite Unstable Colorectal Cancer", "Microsatellite Stable Colorectal Cancer", "Mismatch Repair Proficient Colorectal Cancer", "Mismatch Repair Deficient Colorectal Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "BMS-986016", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 385, "start_date": "2014-03-12", "completion_date": "2024-10-22", "has_results": true, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-10-24T18:04:13.880Z", "location_count": 14, "location_summary": "Gilbert, Arizona • Los Angeles, California • San Francisco, California + 10 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02060188" }, { "nct_id": "NCT00064129", "title": "Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Prostate Carcinoma", "Stage IV Prostate Cancer AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 42, "start_date": "2003-05-13", "completion_date": "2012-10-01", "has_results": false, "last_update_posted_date": "2020-07-30", "last_synced_at": "2026-10-24T18:04:13.880Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00064129" }, { "nct_id": "NCT02314169", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Canal Squamous Cell Carcinoma", "Metastatic Anal Canal Carcinoma", "Stage IV Anal Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2015-05-13", "completion_date": "2027-03-20", "has_results": true, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-24T18:04:13.880Z", "location_count": 55, "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 43 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Derby", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02314169" }, { "nct_id": "NCT07603856", "title": "A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Metastatic Lung Cancer" ], "interventions": [ { "name": "Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab)", "type": "DRUG" }, { "name": "Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments)", "type": "DRUG" }, { "name": "Ablative Hypofractionated Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2026-12-12", "completion_date": "2030-06-25", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-24T18:04:13.880Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07603856" } ] }